

**Title:** COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases:  
A Comparative Cohort Study

**Authors:** Naomi J. Patel, MD<sup>\*†</sup>; Kristin M. D’Silva, MD, MPH<sup>\*†§</sup>; Tiffany Y-T. Hsu, MD, PhD<sup>||</sup>; Michael DiIorio, MD<sup>||</sup>; Xiaoqing Fu, MS<sup>‡§</sup>; Claire Cook, MPH<sup>‡§</sup>; Lauren Prisco, BA<sup>||</sup>; Lily Martin, BS<sup>||</sup>; Kathleen M.M. Vanni, BA<sup>||</sup>; Alessandra Zaccardelli, MS<sup>||</sup>; Yuqing Zhang, ScD<sup>‡§</sup>; Jeffrey A. Sparks, MD, MMSc<sup>†||</sup>; Zachary S. Wallace, MD, MSc<sup>†‡§</sup>

\*These authors contributed equally to this work (co-first authors).

†These authors contributed equally to this work (co-last authors).

**Affiliations:**

<sup>‡</sup>Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA

<sup>§</sup>Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

<sup>||</sup>Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA

All at Harvard Medical School, Boston, MA.

**Supplement**

**Supplemental Table 1. Details of death following COVID-19 in immune-mediated cases treated with CD20 inhibitors and matched comparators.**

	<b>CD20 Inhibitor-Treated Immune-Mediated Case Deaths (n=12)</b>	<b>Matched Comparator Deaths (n=21)</b>
Age, years, mean ± SD	69.0 ± 19.4	77.0 ± 11.7
Female, n (%)	5 (42)	6 (29)
Hospitalized within MGB, n (%)	11 (92)	20 (95)
Mechanically ventilated within MGB, n (%)	4 (33)	8 (38)
“Do not intubate” code status, n (%)	6 (50)	10 (48)

MGB, Mass General Brigham healthcare system; SD, standard deviation; COVID-19, Coronavirus Disease 2019.

**Supplemental Table 2. Risk of death following COVID-19 in patients treated with CD20 inhibitors for rheumatic disease indications versus comparators.**

	<b>CD20 Inhibitor-Treated Rheumatic Disease Cases (n=56)*</b>	<b>Matched Comparators (n=276)</b>
Deaths, n (%)	7 (13)	15 (5)
Total follow-up time (person-days)	7917	42560
Incidence rate/1000 days (95% CI)	0.9 (0.2 to 1.5)	0.4 (0.2 to 0.5)
Unadjusted HR (95% CI)	2.52 (1.07 to 5.90)	Ref
Adjusted model 1 HR (95% CI)†	2.42 (1.02 to 5.74)	Ref
Adjusted model 2 HR (95% CI)	2.02 (0.71 to 5.80)	Ref
Adjusted model 3 HR (95% CI)‡	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Rheumatic disease indication includes 54 patients with rheumatic disease indication only and 2 patients with combined rheumatic and hematologic indications.

† Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

‡ Model 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**Supplemental Table 3. Risk of death following COVID-19 in patients treated with CD20 inhibitors for neurologic disease indications versus comparators.**

	<b>CD20 Inhibitor-Treated Neurologic Disease Cases (n=43)</b>	<b>Matched Comparators (n=211)</b>
Deaths, n (%)	2 (5)	4 (2)
Total follow-up time (person-days)	6551	34051
Incidence rate/1000 days (95% CI)	0.3 (0.0 to 0.7)	0.1 (0.0 to 0.2)
Unadjusted HR (95% CI)	2.41 (0.66 to 8.77)	Ref
Adjusted model 1 HR (95% CI)*	NR	Ref
Adjusted model 2 HR (95% CI)	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2). Adjusted models not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**Supplemental Table 4. Risk of death following COVID-19 in immune-mediated cases treated with CD20 inhibitors for greater than or less than 1 year versus matched comparators.**

	<b>&lt; 1 Year of CD20 Inhibitor Exposure</b>		<b>&gt; 1 Year of CD20 Inhibitor Exposure</b>	
	<b>CD20 Inhibitor-Treated Immune-Mediated Cases (n=81)</b>	<b>Matched Comparators (n=399)</b>	<b>CD20 Inhibitor-Treated Immune-Mediated Cases (n=33)</b>	<b>Matched Comparators (n=160)</b>
Deaths, n (%)	7 (9)	11 (3)	5 (15)	10 (6)
Total follow-up time (person-days)	11088	59458	4730	24714
Incidence rate/1000 days (95% CI)	0.6 (0.2 to 1.1)	0.2 (0.1 to 0.3)	1.1 (0.1 to 2.0)	0.4 (0.2 to 0.7)
Unadjusted HR (95% CI)	2.82 (1.34 to 5.96)	Ref	2.92 (0.95 to 8.99)	Ref
Adjusted model 1 HR (95% CI)*	2.85 (1.35 to 6.01)	Ref	2.90 (0.95 to 8.87)	Ref
Adjusted model 2 HR (95% CI)	2.91 (1.26 to 6.74)	Ref	2.02 (0.61 to 6.70)	Ref
Adjusted model 3 HR (95% CI)†	NR	Ref	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

† Model 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**Supplemental Table 5. Risk of death following COVID-19 in patients treated with CD20 inhibitors and not receiving glucocorticoids versus comparators.**

	<b>CD20 Inhibitor-Treated Cases (n=79)</b>	<b>Matched Comparators (n=384)</b>
Deaths, n (%)	6 (8)	6 (2)
Total follow-up time (person-days)	11878	61304
Incidence rate/1000 days (95% CI)	0.50 (0.10 to 0.90)	0.10 (0.00 to 0.20)
Unadjusted HR (95% CI)	4.37 (1.79 to 10.71)	Ref
Adjusted model 1 HR (95% CI)*	4.43 (1.79 to 10.98)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

† Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**Supplemental Table 6. Risk of death following COVID-19 in patients without cancer treated with CD20 inhibitors versus comparators.**

	<b>CD20 Inhibitor-Treated Cases (n=103)</b>	<b>Matched Comparators (n=502)</b>
Deaths, n (%)	11 (11)	19 (4)
Total follow-up time (person-days)	14558	76981
Incidence rate/1000 days (95% CI)	0.80 (0.30 to 1.20)	0.20 (0.10 to 0.40)
Unadjusted HR (95% CI)	3.00 (1.53 to 5.92)	Ref
Adjusted model 1 HR (95% CI)*	2.99 (1.52 to 5.86)	Ref
Adjusted model 2 HR (95% CI)	2.57 (1.21 to 5.45)	Ref
Adjusted model 3 HR (95% CI)	2.20 (1.00 to 4.85)	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index.

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

**Supplemental Table 7. Risk of death following COVID-19 in patients without interstitial lung disease treated with CD20 inhibitors versus comparators.**

	<b>CD20 Inhibitor-Treated Cases (n=89)</b>	<b>Matched Comparators (n=396)</b>
Deaths, n (%)	6 (7)	7 (2)
Total follow-up time (person-days)	13535	65014
Incidence rate/1000 days (95% CI)	0.40 (0.10 to 0.80)	0.10 (0.00 to 0.20)
Unadjusted HR (95% CI)	3.51 (1.41 to 8.71)	Ref
Adjusted model 1 HR (95% CI)*	3.45 (1.36 to 8.73)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

† Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**Supplemental Table 8. Risk of death following COVID-19 in patients treated with most recent CD20 inhibitor dose within 3 months of COVID-19 infection versus comparators.**

	CD20 Inhibitor-Treated Cases (n=48)	Matched Comparators (n=235)
Deaths, n (%)	7 (15)	6 (3)
Total follow-up time (person-days)	6099	34753
Incidence rate/1000 days (95% CI)	1.10 (0.30 to 2.00)	0.20 (0.00 to 0.30)
Unadjusted HR (95% CI)	9.59 (2.98 to 30.85)	Ref
Adjusted model 1 HR (95% CI)*	9.79 (3.00 to 31.93)	Ref
Adjusted model 2 HR (95% CI)†	NR	Ref
Adjusted model 3 HR (95% CI)	NR	Ref

HR, hazard ratio; CI, confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; Ref, reference; NR, not reported

\* Model 1 adjusted for age. Model 2 adjusted for age and race. Model 3 adjusted for age, race, BMI, and CCI (dichotomized as <2 or ≥2).

† Models 2 and 3 not reported due to insufficient number of outcomes (<7 outcomes per adjusted covariate).

**\*\*\*\*POTENTIAL Supplemental Table 9. Immune-mediated disease status at the time of COVID-19 diagnosis by timing of most recent rituximab dose prior to infection. \*\*\*\***

	Most recent CD20 inhibitor dose < 3 months prior to COVID-19 (n=48)	Most recent CD20 inhibitor dose 3-6 months prior to COVID-19 (n=44)	Most recent CD20 inhibitor dose 6-12 months prior to COVID-19 (n=22)	P-value
Immune-mediated disease status				0.23
Remission	13 (27)	7 (16)	6 (27)	
Low activity	19 (40)	28 (64)	11 (50)	
Moderate/high activity	16 (33)	9 (20)	5 (23)	

Number of death	Most recent CD20 inhibitor dose < 3 months prior to COVID-19 (n=48)	Most recent CD20 inhibitor dose 3-6 months prior to COVID-19 (n=44)	Most recent CD20 inhibitor dose 6-12 months prior to COVID-19 (n=22)
Immune-mediated disease status			
Remission	1 (2)	1 (2)	0 (0)

Low activity	1 (2)	2 (4)	0 (0)
Moderate/high activity	5 (10)	1 (2)	1 (5)